Kymera Therapeutics (KYMR) Free Cash Flow Growth (3y) (2022 - 2026)

Kymera Therapeutics (KYMR) Free Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -1.95%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -20.15%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 45.09%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 12.85%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -4.45%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 80.69%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 8.92%
10 Kymera Therapeutics 9.72 Bn 9.03 Bn - -4.09%

Historic Data

Download Data
DateValue
Jun 30, 2026 -4.09%
Mar 31, 2026 -23.00%
Dec 31, 2025 -23.99%
Sep 30, 2025 8.41%
Jun 30, 2025 -15.11%
Mar 31, 2025 -24.99%
Dec 31, 2024 -16.91%
Sep 30, 2024 -10.00%
Jun 30, 2024 -15.22%
Mar 31, 2024 -26.92%
Dec 31, 2023 39.59%
Sep 30, 2023 -28.68%
Jun 30, 2023 -44.46%
Mar 31, 2023 -52.79%
Dec 31, 2022 -51.26%